Aryl Hydrocarbon Receptor Signaling in Prostate Cancer Therapy: A Review of Implications for Anti-androgen Treatment Strategies and Resistance

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 Aug 26

PMID 39184676

Authors

Gurjot Singh

Shubam Trehan

Adarshpreet Singh

Kanishka Goswami

Amna Farooq

Priya Antil

Piyush Puri

Gaurav Bector

Aayush Jain

Waqas Azhar

Affiliations

Soon will be listed here.

Abstract

Prostate cancer is a leading cause of cancer-related morbidity and mortality in men, frequently exhibiting resistance to conventional anti-androgen therapies. This review investigates the emerging significance of the aryl hydrocarbon receptor (AhR) in prostate cancer, focusing on its role in modulating androgen receptor (AR) signaling and its potential as a therapeutic target. AhR, traditionally known for detoxifying harmful compounds, has been increasingly recognized for its dual capacity to either enhance or inhibit AR activity based on cellular context and specific coactivators. Furthermore, AhR influences tumor progression independently of AR by regulating genes involved in cell cycle control and apoptosis. This narrative review synthesizes current research on AhR's multifaceted roles in prostate cancer, evaluates its potential as a biomarker, and discusses the therapeutic implications of targeting AhR, particularly for hormone-refractory prostate cancer. Our findings underscore the necessity for personalized AhR-targeted therapies and advocate for continued clinical research to fully leverage AhR's therapeutic potential.

References

Nguyen L, Bradfield C . The search for endogenous activators of the aryl hydrocarbon receptor. Chem Res Toxicol. 2007; 21(1):102-16. PMC: 2572005. DOI: 10.1021/tx7001965. View

Matthews J, Gustafsson J . Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol Interv. 2004; 3(5):281-92. DOI: 10.1124/mi.3.5.281. View

Elson D, Kolluri S . Tumor-Suppressive Functions of the Aryl Hydrocarbon Receptor (AhR) and AhR as a Therapeutic Target in Cancer. Biology (Basel). 2023; 12(4). PMC: 10135996. DOI: 10.3390/biology12040526. View

de Bono J, Logothetis C, Molina A, Fizazi K, North S, Chu L . Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364(21):1995-2005. PMC: 3471149. DOI: 10.1056/NEJMoa1014618. View

Yu J, Qi H, Wang Z, Zhang Z, Song E, Song W . RAB3D, upregulated by aryl hydrocarbon receptor (AhR), promotes the progression of prostate cancer by activating the PI3K/AKT signaling pathway. Cell Biol Int. 2022; 46(12):2246-2256. DOI: 10.1002/cbin.11910. View

Shahin N, Abd-Elwahab G, Tawfiq A, Abdelgawad H . Potential role of aryl hydrocarbon receptor signaling in childhood obesity. Biochim Biophys Acta Mol Cell Biol Lipids. 2020; 1865(8):158714. DOI: 10.1016/j.bbalip.2020.158714. View

Sharifi N, Gulley J, Dahut W . Androgen deprivation therapy for prostate cancer. JAMA. 2005; 294(2):238-44. DOI: 10.1001/jama.294.2.238. View

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

Fizazi K, Scher H, Molina A, Logothetis C, Chi K, Jones R . Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012; 13(10):983-92. DOI: 10.1016/S1470-2045(12)70379-0. View

10.

Murray I, Patterson A, Perdew G . Aryl hydrocarbon receptor ligands in cancer: friend and foe. Nat Rev Cancer. 2015; 14(12):801-14. PMC: 4401080. DOI: 10.1038/nrc3846. View

11.

Devlies W, Handle F, Devos G, Joniau S, Claessens F . Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer. Cancers (Basel). 2021; 13(4). PMC: 7926818. DOI: 10.3390/cancers13040915. View

12.

Zgarbova E, Vrzal R . The Impact of Indoles Activating the Aryl Hydrocarbon Receptor on Androgen Receptor Activity in the 22Rv1 Prostate Cancer Cell Line. Int J Mol Sci. 2023; 24(1). PMC: 9820252. DOI: 10.3390/ijms24010502. View

13.

Safe S, Han H, Goldsby J, Mohankumar K, Chapkin R . Aryl Hydrocarbon Receptor (AhR) Ligands as Selective AhR Modulators: Genomic Studies. Curr Opin Toxicol. 2019; 11-12:10-20. PMC: 6709982. DOI: 10.1016/j.cotox.2018.11.005. View

14.

Shinde R, McGaha T . The Aryl Hydrocarbon Receptor: Connecting Immunity to the Microenvironment. Trends Immunol. 2018; 39(12):1005-1020. PMC: 7182078. DOI: 10.1016/j.it.2018.10.010. View

15.

Gelmann E . Molecular biology of the androgen receptor. J Clin Oncol. 2002; 20(13):3001-15. DOI: 10.1200/JCO.2002.10.018. View

16.

Chen Z, Cai A, Zheng H, Huang H, Sun R, Cui X . Carbidopa suppresses prostate cancer via aryl hydrocarbon receptor-mediated ubiquitination and degradation of androgen receptor. Oncogenesis. 2020; 9(5):49. PMC: 7220950. DOI: 10.1038/s41389-020-0236-x. View

17.

Kirby M, Hirst C, Crawford E . Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011; 65(11):1180-92. DOI: 10.1111/j.1742-1241.2011.02799.x. View

18.

Prochazkova J, Kahounova Z, Vondracek J, Soucek K . Aryl hydrocarbon receptor as a drug target in advanced prostate cancer therapy - obstacles and perspectives. Transcription. 2024; :1-20. DOI: 10.1080/21541264.2024.2334106. View

19.

Narasimhan S, Stanford Zulick E, Novikov O, Parks A, Schlezinger J, Wang Z . Towards Resolving the Pro- and Anti-Tumor Effects of the Aryl Hydrocarbon Receptor. Int J Mol Sci. 2018; 19(5). PMC: 5983651. DOI: 10.3390/ijms19051388. View

20.

Heinlein C, Chang C . Androgen receptor in prostate cancer. Endocr Rev. 2004; 25(2):276-308. DOI: 10.1210/er.2002-0032. View